Literature DB >> 22161972

Biochemical relapse following radical prostatectomy and miR-200a levels in prostate cancer.

Niall Barron1, Joanne Keenan, Patrick Gammell, Vanesa G Martinez, Alex Freeman, John R Masters, Martin Clynes.   

Abstract

BACKGROUND: Radical prostatectomy cures the majority of men with clinically localized disease, but up to 30% of men relapse with rising serum PSA levels. Stage, Gleason grade, and pre-operative PSA levels are associated with outcome but do not accurately predict which individuals will relapse. MicroRNA (miRNA) levels are altered in cancer and are associated with progression of disease. The miR-200 family has roles in prostate cancer.
METHODS: miR-200a levels were measured in 18 radical prostatectomy samples from men who did not relapse and from 18 who did relapse, matched for stage (all T3), grade, and PSA levels. A pair of cancer and normal prostate cell lines derived from the same radical prostatectomy specimen were transfected with miR-200a to determine the effects on growth, wound healing, and invasion.
RESULTS: Comparing the matched samples, 11 of the relapsers contained lower, 2 higher and 5 similar levels to the non-relapsers. Transient transfection of miR-200a significantly reduced cell proliferation in prostate cancer cell lines but did not affect invasiveness.
CONCLUSION: miR-200a overexpression reduced prostate cancer cell growth and may have potential, in combination with other markers, in stratifying prostate cancer patients for more intensive monitoring and therapy.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22161972     DOI: 10.1002/pros.22469

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  30 in total

1.  MiRNA-200a induce cell apoptosis in renal cell carcinoma by directly targeting SIRT1.

Authors:  Hao Fu; Wenke Song; Xuancai Chen; Tao Guo; Bin Duan; Xinxi Wang; Yachun Tang; Liang Huang; Chi Zhang
Journal:  Mol Cell Biochem       Date:  2017-07-17       Impact factor: 3.396

Review 2.  The roles of microRNAs in the progression of castration-resistant prostate cancer.

Authors:  Satoko Kojima; Yusuke Goto; Yukio Naya
Journal:  J Hum Genet       Date:  2016-06-09       Impact factor: 3.172

3.  Tumor suppressive microRNA-200a inhibits renal cell carcinoma development by directly targeting TGFB2.

Authors:  Ruijing Lu; Ziliang Ji; Xiaoqing Li; Jie Qin; Guanghui Cui; Jing Chen; Qingna Zhai; Chunjuan Zhao; Wei Zhang; Zhendong Yu
Journal:  Tumour Biol       Date:  2015-03-27

4.  Combinations of elevated tissue miRNA-17-92 cluster expression and serum prostate-specific antigen as potential diagnostic biomarkers for prostate cancer.

Authors:  Sujuan Feng; Xiaosong Qian; Han Li; Xiaodong Zhang
Journal:  Oncol Lett       Date:  2017-09-22       Impact factor: 2.967

Review 5.  MicroRNAs as predictive biomarkers and therapeutic targets in prostate cancer.

Authors:  Xin Wen; Fang-Ming Deng; Jinhua Wang
Journal:  Am J Clin Exp Urol       Date:  2014-10-02

Review 6.  Epigenetic mechanisms in commonly occurring cancers.

Authors:  Lauren P Blair; Qin Yan
Journal:  DNA Cell Biol       Date:  2012-04-20       Impact factor: 3.311

7.  microRNAs and Prostate Cancer.

Authors:  Sajni Josson; Leland W K Chung; Murali Gururajan
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

Review 8.  MiR-200, a new star miRNA in human cancer.

Authors:  Xiangling Feng; Zhengming Wang; Rebecca Fillmore; Yaguang Xi
Journal:  Cancer Lett       Date:  2013-11-19       Impact factor: 8.679

9.  Members of the microRNA-200 family are promising therapeutic targets in cancer.

Authors:  Ying Chen; Lei Zhang
Journal:  Exp Ther Med       Date:  2017-05-22       Impact factor: 2.447

Review 10.  miRNAs as biomarkers in prostate cancer.

Authors:  Irene Casanova-Salas; José Rubio-Briones; Antonio Fernández-Serra; Jose Antonio López-Guerrero
Journal:  Clin Transl Oncol       Date:  2012-07-24       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.